Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 31,784 shares, a drop of 61.2% from the June 30th total of 81,924 shares. Based on an average trading volume of 9,525 shares, the short-interest ratio is currently 3.3 days.
Relief Therapeutics Stock Up 12.1%
OTCMKTS RLFTF opened at $0.22 on Tuesday. Relief Therapeutics has a twelve month low of $0.16 and a twelve month high of $4.88. The stock has a 50-day moving average of $0.34 and a 200 day moving average of $0.72.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
See Also
- Five stocks we like better than Relief Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
